{
    "id": 25267,
    "fullName": "MSLN over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MSLN over exp indicates an over expression of the Msln protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10232,
        "geneSymbol": "MSLN",
        "terms": [
            "MSLN",
            "MPF",
            "SMRP"
        ]
    },
    "variant": "over exp",
    "createDate": "08/20/2016",
    "updateDate": "01/08/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7850,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anetumab ravtansine inhibited survival of pancreatic carcinoma cells over expressing Msln (mesothelin) in culture and resulted in tumor eradication in cell line and patient-derived xenograft models (PMID: 24714131).",
            "molecularProfile": {
                "id": 26076,
                "profileName": "MSLN over exp"
            },
            "therapy": {
                "id": 4593,
                "therapyName": "Anetumab ravtansine",
                "synonyms": null
            },
            "indication": {
                "id": 4905,
                "name": "pancreatic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6512,
                    "pubMedId": 24714131,
                    "title": "Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24714131"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7852,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anetumab ravtansine inhibited survival of pancreatic carcinoma cells over expressing Msln (mesothelin) in culture and resulted in tumor regression in cell line and patient-derived xenograft models (PMID: 24714131).",
            "molecularProfile": {
                "id": 26076,
                "profileName": "MSLN over exp"
            },
            "therapy": {
                "id": 4593,
                "therapyName": "Anetumab ravtansine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6512,
                    "pubMedId": 24714131,
                    "title": "Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24714131"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7851,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anetumab ravtansine inhibited survival of ovarian cancer cells over expressing Msln (mesothelin) in culture and resulted in tumor eradication in cell line and patient-derived xenograft models (PMID: 24714131).",
            "molecularProfile": {
                "id": 26076,
                "profileName": "MSLN over exp"
            },
            "therapy": {
                "id": 4593,
                "therapyName": "Anetumab ravtansine",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6512,
                    "pubMedId": 24714131,
                    "title": "Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24714131"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7853,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anetumab ravtansine inhibited survival of mesothelioma cells over expressing Msln (mesothelin) in culture and resulted in tumor regression in cell line and patient-derived xenograft models (PMID: 24714131).",
            "molecularProfile": {
                "id": 26076,
                "profileName": "MSLN over exp"
            },
            "therapy": {
                "id": 4593,
                "therapyName": "Anetumab ravtansine",
                "synonyms": null
            },
            "indication": {
                "id": 1790,
                "name": "malignant mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6512,
                    "pubMedId": 24714131,
                    "title": "Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24714131"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26076,
            "profileName": "MSLN over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}